MedTrace Logo

Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study

NCT02083874 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2014-03-11

No results posted yet for this study

Summary

Single subject repeated measures design of an open label administration of Cannabidiol (CBD) to 5 participants withdrawing from cannabis use in an inpatient setting. 300mg of CBD will be administered once on day 1, twice on days 2-5 and once on day 6. Participants will be discharged on day 7. CBD will be administered orally in capsules.

Conditions

  • Cannabis Use Disorder

Interventions

DRUG

CBD

Sponsors & Collaborators

  • The University of New South Wales

    lead OTHER

Principal Investigators

  • Martin Weltman, PhD MD · Nepean Blue Mountains Local Health District

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-09-30
Completion
2014-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083874 on ClinicalTrials.gov